The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia

Psychiatry Research

Volumn 210, Issue 2, 2013, Pages 396-401

  Hatta, Kotaro ^a   Takebayashi, Hiroshi ^b   Sudo, Yasuhiko ^c   Katayama, Shigemasa ^d   Kasuya, Masataka ^e   Shirai, Yutaka ^f   Morikawa, Fumiyoshi ^g   Nakase, Reiko ^h   Nakamura, Masato ⁱ   Ito, Shin ^j   Kuga, Hironori ^k   Nakamura, Mitsuru ^l   Ohnuma, Tohru ^m   Usui, Chie ^a   Nakamura, Hiroyuki ⁿ   Hirata, Toyoaki ^o   Sawa, Yutaka ^p  

^a JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^b Saitama Prefectural Psychiatric Hospital   (Japan)

^c Tosa Hospital   (Japan)

^d Seijin Hospital   (Japan)

^e Tokyo Musashino Hospital   (Japan)

^f Hyogo Prefectural Amagasaki Hospital   (Japan)

^g Department of Psychiatry   (Japan)

^h Mie Pref General Medical Center   (Japan)

ⁱ Narimasu Kousei Hospital   (Japan)

^j Yamada Hospital   (Japan)

^k National Hospital Organization Hizen Psychiatric Center   (Japan)

^l Toshima Tokyo Metropolitan Hospital   (Japan)

^m JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^o Chiba Psychiatric Medical Center   (Japan)

^p Sawa Hospital   (Japan)

more..

Author keywords

Emergency; Negative symptom; Randomized clinical trial; Risperidone; Serum concentration

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MULTICENTER STUDY; NEGATIVE SYNDROME; OVERSEDATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TREATMENT DURATION; ACUTE DISEASE; BLOOD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; EMERGENCY HEALTH SERVICE; FEMALE; MALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS; YOUNG ADULT;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMERGENCY SERVICES, PSYCHIATRIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84886946645     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.07.005     Document Type: Article

References (31)

1. Bigos K.L., Bies R.R., Pollock B.G., Lowy J.J., Zhang F., Weinberger D.R. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Molecular Psychiatry 2011, 16:620-625.
2. Cahn W., van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Caspers E., Laponder D.A., Kahn R.S. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. British Journal of Psychiatry 2006, 189:381-382.
3. Callaghan J.T., Bergstrom R.F., Ptak L.R., Beasley C.M. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clinical Pharmacokinetics 1999, 37:177-193.
4. Citrome L., Jaffe A., Levine J. Datapoints: the ups and downs of dosing second-generation antipsychotics. Psychiatric Services 2007, 58:11.
5. Citrome L., Stauffer V.L., Chen L., Kinon B.J., Kurtz D.L., Jacobson J.G., Bergstrom R.F. Olanzapine plasma concentrations after treatment with 10, 20, and 40mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. Journal of Clinical Psychopharmacology 2009, 29:278-283.
6. Choi H.J., Jung S.H., Kang M.H., Lee J.S., Bae J.N., Kim C.E. Antipsychotics prescribing patterns of patients with schizophrenia admitted to Korean general hospital psychiatric unit: 2001 to 2008. Clinical Psychopharmacology and Neuroscience 2011, 9:17-22.
7. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. American Journal of Psychiatry 2010, 167:686-693.
8. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, US Dept of Health, Education, and Welfare, Bethesda.
9. Hatta K., Nakamura H., Matsuzaki I. Acute-phase treatment in general hospitals: clinical psychopharmacologic evaluation in first-episode schizophrenia patients. General Hospital Psychiatry 2003, 25:39-45.
10. Hatta K., Otachi T., Sudo Y., Hayakawa T., Ashizawa Y., Takebayashi H., Hayashi N., Hamakawa H., Ito S., Nakase R., Usui C., Nakamura H., Hirata T., Sawa Y. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophrenia Research 2011, 128:127-135.
11. Hatta, K., Otachi, T., Sudo, Y., Kuga, H., Takebayashi, H., Hayashi, H., Ishii, R., Kasuya, M., Hayakawa, T., Morikawa, F., Hata, K., Nakamura, M., Usui, C., Nakamura, H., Hirata, T., Sawa, Y., 2012. A Comparison Between Augmentation with Olanzapine and Increased Risperidone Dose in Acute Schizophrenia Patients Showing Early Non-response to Risperidone. Psychiatry Research Mar. 13. (Epub ahead of print] PMID: 22421064). For the JAST Study Group.
12. Hatta K., Sato K., Hamakawa H., Takebayashi H., Kimura N., Ochi S., Sudo Y., Asukai N., Nakamura H., Usui C., Kawabata T., Hirata T., Sawa Y. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophrenia Research 2009, 113:49-55.
13. Hatta K., Takahashi T., Nakamura H., Yamashiro H., Endo H., Fujii S., Fukami G., Masui K., Asukai N., Yonezawa Y. Abnormal physiological conditions in acute schizophrenic patients on emergency admission: dehydration, hypokalemia, leukocytosis and elevated serum muscle enzymes. European Archives of Psychiatry and Clinical Neuroscience 1998, 248:180-188.
14. Inada T. Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage 1996, Seiwa Shoten Publishers, Tokyo.
15. Jones S.H., Thornicroft G., Coffey M., Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). British Journal of Psychiatry 1995, 166(5):654-659.
16. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual 1991, Multi-Health System Inc., Toronto.
17. Kelly D.L., Richardson C.M., Yu Y., Conley R.R. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Human Psychopharmacology: Clinical and Experimental 2006, 21:393-398.
18. Kinon B.J., Kane J.M., Chakos M., Munne R. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacology Bulletin 1993, 29:365-369.
19. Kinon B.J., Volavka J., Stauffer V., Edwards S.E., Liu-Seifert H., Chen L., Adams D.H., Lindenmayer J.P., McEvoy J.P., Buckley P.F., Lieberman J.A., Meltzer H.Y., Wilson D.R., Citrome L. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. Journal of Clinical Psychopharmacology 2008, 28:392-400.
20. Kraus J.E., Sheitman B.B., Cook A., Reviere R., Lieberman J.A. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. Journal of Clinical Psychiatry 2005, 66:1564-1568.
21. Kumra S., Kranzler H., Gerbino-Rosen G., Kester H.M., De Thomas C., Kafantaris V., Correll C.U., Kane J.M. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biological Psychiatry 2008, 63:524-529.
22. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatrica Scandinavica 2009, 119(Suppl 438):7-14.
23. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005, 353:1209-1223.
24. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clinical Pharmacokinetics 2007, 46:359-388.
25. McCue R.E., Waheed R., Urcuyo L., Orendain G., Joseph M.D., Charles R., Hasan S.M. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. British Journal of Psychiatry 2006, 189:433-440.
26. Mitchell M., Riesenberg R., Bari M.A., Marquez E., Kurtz D., Falk D., Hardy T., Taylor C.C., Mitchell C.P., Cavazzoni P. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40mg/d oral olanzapine relative to 20mg/d oral olanzapine in stable psychiatric subjects. Clinical Therapeutics 2006, 28:881-892.
27. Meltzer H.Y., Bobo W.V., Roy A., Jayathilake K., Chen Y., Ertugrul A., Anil Yaǧcioǧlu A.E., Small J.G. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Journal of Clinical Psychiatry 2008, 69:274-285.
28. Roth B.L. High-dose olanzapine for treatment-resistant schizophrenia. Journal of Clinical Psychiatry 2008, 69:176-177.
29. Skogh E., Sjödin I., Josefsson M., Dahl M.L. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. Journal of Clinical Psychopharmacology 2011, 31:4-9.
30. Suzuki T., Remington G., Mulsant B.H., Rajji T.K., Uchida H., Graff-Guerrero A., Mamo D.C. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophrenia Research 2011, 133:54-62.
31. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry 2002, 159:255-262.